MAP1A

Across TCGA pan-cancer cohorts, MAP1A RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of MAP1A’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MAP1A RNA is repressed in tumor relative to normal tissue. In most cancer types MAP1A is over-expressed in tumor, although a few such as BLCA and THCA show the opposite, repressed pattern.

BLCA, THCA, and LIHC are the cancer types where MAP1A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP1A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	IV	−3.795	<.001	8	view →
THCA	Male	II,III,IV	−1.601	<.001	8	view →
LIHC	All	All	+0.554	<.001	8	view →
KIRP	All	II,III,IV	+0.811	.004	7	view →
CHOL	Male	All	+1.535	<.001	5	view →
COAD	All	II,III,IV	−0.812	.002	5	view →
UCEC	All	All	−1.801	<.001	4	view →
BRCA	All	All	−0.441	<.001	4	view →
KICH	All	All	−0.635	.002	3	view →
HNSC	All	II,III,IV	+0.618	.039	3	view →
READ	Female	All	−2.401	.004	2	view →
PRAD	All	All	−0.993	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

MAP1A–BLCA

Open the BLCA breakdown →